Furthermore, despite the clinical benefits achieved by CFTR modulators, CF patients continue to suffer from chronic bacterial infections and heightened inflammation leading to recurrent sinopulmonary morbidity and ultimately mortality. This evidence concerns the gene CFTR and cystic fibrosis.